Dutch Biotech takes RSV vaccine nasal spray vaccine into Ph I trial

By Dani Bancroft

- Last updated on GMT

iStock/RusN
iStock/RusN

Related tags: Antibody, Immune system

Mucosis B.V. has started a volunteer study of SynGEM, a respiratory syncytial virus (RSV) vaccine formulated for nasal delivery.

The UK-based study Phase I study - which is part funded by a grant from the Wellcome Trust​ – is designed to assess both SynGEM and the nasal delivery device - Teleflex VaxINator – in a real world setting according to Mucosis CEO, Tom Johnston.

Mucosis developed SynGEM using its proprietary probiotics-based technology, Mimopath. The vaccine consists of a pre-fusion version of an RSV antigen formulated for intranasal delivery.

Formulation development was a complex process according to Johnston, who said: “One of the challenges with pre-fusion F antigens has been its natural lack of stability.  Mucosis was able to engineer around this to create a stable antigen and patent this design​.”

The firm claims pre-fusion RSV antigens produced using the Mimopath technology stimulate production of antibodies against the virus more effectively than post-fusion versions of the same protein.

Why Needle-Free

The Teleflex VaxINator Intranasal Mucosal Atomisation Device (MAD) uses pressure to aerosolize the vaccine as a ‘fine mist’ that can be delivered to the nasal passageways directly.

Studies​ have shown that introducing RSV antibodies via the mucous membranes generates a better systemic immune response.

In addition, the research also demonstrated that a raised antibody response in the mucous membranes helps block entry of the virus, thereby providing an effective first-line of defence.

This has prompted several other companies to pursue intranasal products – such as AstraZeneca’s nasal flu spray​, Fluenz Tetra, or the Belgian biotech Ablynx’s therapy for RSV, due to start a Phase IIb efficacy study later this year.

Similarly, Ablynx’s nanobody product ALX-0171 – which is a post infection RSV antiviral therapy - has also been formulated for intranasal delivery.

Related topics: Drug Delivery, Delivery technologies

Related news

Show more

Related products

show more

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us

Products

View more

Webinars